论文部分内容阅读
目的分析二甲双胍联合多烯磷脂酰胆碱对非酒精性脂肪肝患者的治疗作用。方法符合诊断标准的肥胖型非酒精性脂肪肝患者80例分为两组,试验组40例联合多烯磷脂酰胆碱及二甲双胍,对照组40例服用多烯磷脂酰胆碱及维生素C片,疗程均为4～6个月。治疗前后测定各组患者血清转氨酶水平(ALT、AST)、血脂水平(TG、TC、LDL-C及HDL-C)、胰岛素抵抗指数(IRI)及肝/脾cT比值并作统计学处理,同时观察实验过程中出现的不良反应。结果治疗后两组患者血清ALT均明显降低,尤以试验组降低明显(P<0.01);试验组患者治疗后各项血脂水平均显著改善;试验组胰岛素抵抗指数于治疗后明显下降(P<0.05),而对照组无明显改变(P>0.05);同时试验组治疗后肝/脾CT比值显著升高(P<0.01)。结论二甲双胍联合多烯磷脂酰胆碱对非酒精性脂肪肝有显著疗效且用药安全。
Objective To investigate the therapeutic effect of metformin combined with polyene phosphatidylcholine on non-alcoholic fatty liver disease. Methods Eighty patients with obese non-alcoholic fatty liver who met the diagnostic criteria were divided into two groups: 40 in combination with polyene phosphatidylcholine and metformin in trial group, 40 in polyarylene phosphatidylcholine and vitamin C in control group, Treatment are 4 to 6 months. Serum aminotransferase (ALT, AST), blood lipid levels (TG, TC, LDL-C and HDL-C), insulin resistance index (IRI) and liver / spleen cT ratio were measured before and after treatment. Observe the adverse reactions during the experiment. Results After treatment, serum ALT in both groups decreased significantly, especially in the experimental group (P <0.01). The levels of serum lipids in the experimental group were significantly improved after treatment. The insulin resistance index of the experimental group decreased significantly after treatment (P < 0.05), while there was no significant change in the control group (P> 0.05). Meanwhile, the ratio of liver to spleen in the experimental group was significantly increased (P <0.01). Conclusions Metformin combined with polyene phosphatidylcholine has a significant effect on non-alcoholic fatty liver and is safe to treat.